An Open Clinical Trial of Poly Herbal Siddha Drugs “Venpoosani Legiyam” (Internal Medicine) and “Ulunthu Thylam” (External Medicine) in the Treatment of Ven Neer Noi (Dhat Syndrome) with and Without Psycho-Education Therapy
DOI:
https://doi.org/10.70135/seejph.vi.3839Abstract
Background: Current research suggests that the Venneer Noi may be related to Dhat Syndrome. The present study was conducted to evaluate the Efficacy of Poly Herbal Siddha Drugs “Venpoosani Legiyam” (Internal Medicine) And “Ulunthu Thylam” (External Medicine) In the Treatment of Venneer Noi (Dhat Syndrome) With and Without Psycho-Education Therapy.
Methodology: Among the 40 patients, 20 patients received trial medicines only and the remaining (randomised) 20 patients received the prescribed Psychoeducation / Counselling therapy along with trial medicines. Each randomly selected 20 patients received the Psychoeducation / Counselling session six times per week from the 2nd visit for the trial medicine to 7th visit. Laboratory investigations were done before and after the trial.
Results: The mean± standard deviation of DSSC score at before and after treatment were 80.20±15.7 and 33.40±11.30 respectively which is statistically extremely significant (t=19.71, p=0.0001). The mean± standard deviation of VCSS score at before and after treatment were 33.75±5.0 and 12.15±4.36 respectively which is statistically extremely significant (t=13.48, p=0.0001).
Discussion: The outcome of this study was clinically observed by DSSC Score, which showed encouraging results of good improvement in 28 patients (70%), moderate improvement in 12 patients (30%). This Psycho- education / Counseling results shown 80 % (16 patients) is good improvement.
Conclusion: The present clinical study supports the efficacy of the trial drugs, Venpoosani Legiyam (internal medicine) and Ulunthu Thylam (external medicine), both of which are Siddha polyherbal formulations.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.